A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Read time: 1 mins
Last updated:9th Jul 2012
Evaluate the efficacy and safety of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS).
|Study start date||2012-07-09|